FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Data integrity roundup: FDA’s guidance note, problems in China and record approvals in 2015
Data integrity – currently the hottest topic in quality
management – should be a straig
FDA’s Drug Approvals in 2015: Novel Drugs & New Versions of Existing Drugs
Each year,
the US Food and Drug Administration (FDA) approve hundreds
of new medications. A small su
Novartis’ plant shut down creates urgency to find alternatives to Chinese APIs
With Novartis shutting two plants in Germany and one in India by 2016-end, the global reliance on Ch